Thursday, 15 October 2026European Markets

TELEVERBIER Stock Went Up By Over 9% So Far On Thursday

Loading stream...

(vianews) - shares of televerbier (cac 40: tvrb.pa) rose 9.68% to €47.60 at 14:08 est on thursday, after five sequential sessions in a row of losses. cac 40 is rising 0.36% to €7,353.35, after two consecutive sessions in a row of gains. this seems, up to now, a somewhat bullish trend trading session today.

about televerbier

téléverbier sa engages in the operation of ski lifts in switzerland. the company is involved in the car parks and locker activities; rental of operating buildings and building surfaces; operation of ski schools; sale and rental of sporting goods; operation of eleven high-altitude restaurants; and sale of catering products, as well as offers catering and accommodation services. it also operates garage workshop and spare parts store for the maintenance of piste groomers; metal construction workshop; and provides maintenance services for ski lift installations. téléverbier sa was incorporated in 1950 and is headquartered in verbier, switzerland.

earnings per share

as for profitability, televerbier has a trailing twelve months eps of €7.58.

pe ratio

televerbier has a trailing twelve months price to earnings ratio of 6.28. meaning, the purchaser of the share is investing €6.28 for every euro of annual earnings.

more news about televerbier (tvrb.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com